natgillin/translations-raw huggingface dataset:
providing a urease-deficient bacterial cell; inserting a recombinant nucleic acid molecule into said bacterial cell, said nucleic acid molecule encoding a fusion polypeptide comprising (a) at least one domain from a polypeptide, wherein said domain is capable of eliciting an immune response in a mammal, and (b) a phagolysosomal escape domain, and 
(ii) umetanje rekombinantne molekule nukleinske kiseline u tu bakterijsku stanicu, a spomenuta molekula nukleinske kiseline kodira fuzijski polipeptid koji obuhvaća (a) najmanje jednu domenu polipeptida, pri čemu ta polipetidna domena ima sposobnost izazvati imuni odgovor kod sisavca, i (b) domenu za bijeg iz fagolizosoma, i
Use of a conditional replication defective CMV of any of claims 1-10 in the manufacture of a medicament for inducing a protective immune response in a patient against CMV infection. 
Kompozicija za uporabu prema patentnom zahtjevu 4, naznačena time što je imunološki odgovor zaštitni imunološki odgovor kod pacijenta protiv CMV infekcije.
A pharmaceutical composition for use according to claim 25 wherein the disease or disorder is COPD. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 32, naznačen time što je bolest ili poremećaj COPD.
Also EP-B-0409903 claims a process, through which oils of animal and/or vegetable origin are undergone to alkaline hydrolysis and the obtained acids are undergone to one or more steps of molecular distillation. 
HR P20080415 T3 Također EP-B-0409903 štiti postupak, u kojem se ulja životinjskog i/ili biljnog porijekla podvrgavaju alkalnoj hidrolizi i dobivene kiseline se podvrgavaju jednom ili više koraka molekularne destilacije.
20-60% preferably 30-50% by weight on a dry weight basis of the hydroxypropyl methylcellulose with an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 2% solution, 
hidroksipropil metilcelulozu količinom od oko 240 mg, pri čemu hidroksipropil metilceluloza ima očit viskozitet od 80,000 cP do 120,000 cP (nominalna vrijednost 100,000 cP) kada je prisutna u 1%-tnoj otopini; mikrokristaliničnu celulozu količinom od 180 mg;
A method according to claim 8, wherein the adjusted dose is equal to the first dose if the variable B is negative and is equal to the second dose if the variable B is positive. 
Metoda sukladno zaštiti 8, naznačena time što je prilagođena doza jednaka prvoj dozi ako je varijabla B negativna te je jednaka drugoj dozi ako je varijabla B pozitivna.
The angiotensin II receptor 1 (AT-1) antagonist for the use as a medicament according to claim 1, wherein the angiotensin II receptor 1 (AT-1) antagonist is selected from the group consisting of: candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, and a pharmaceutically acceptable salt thereof. 
Sartan za uporabu prema zahtjevu 1, naznačen time, da je sartan odabran iz skupine koju čine: kandesartan, eprosartan, irbesartan, losartan, tazosartan, telmisartan, valsartan i njihova farmaceutski prihvatljiva sol. Sartan za uporabu prema zahtjevu 1 ili 2, naznačen time, da sartan je telmisartan ili njegova farmaceutski prihvatljiva sol.
wherein the fraction of viable cells in the tissue-engineered product can be calculated according to the formula: EPMATHMARKEREP wherein EPMATHMARKEREP and f is the fraction of the total conditioned medium present in the portion of the cell culture conditioned medium not containing cells of the cell population. 
K-cY K+Y pri čemu 1-f Cc= E eona f i fje udio ukupnog kondicioniranog medija koji je prisutan u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice iz populacije stanica.
When packed into the tube, this substrate was about 6.5 mm long. 
Kada je pakiran u cijev, ovaj supstrat je bio dug oko 6.5 mm.
The process of any one of claims 1-4, wherein the solution is 10-36% hydrobromic acid in acetate acid. 
Postupak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da otopina bromovodične kiseline u octenoj kiselini jest 10%-36%-tna bromovodična kiselina u octenoj kiselini.
The use according to Claim 25, wherein the medication is for the re-establishment of digestive homeostasis affected by peptic acid disorders and/or states of disorder caused by damages to the gastric mucosa or digestive epithelium. The use according to Claim 25, wherein the medication is for relieving gastroesophageal reflux or GERD symptoms. 
Uporaba prema zahtjevu 14, gdje je lijek za ponovno uspostavljanje homeostaze probave koja je poremećena zbog poremećaja želučane kiseline i/ili stanja koja su uzrokovana oštećenjem želučane sluznice ili probavnog epitela, kao što je gastroezofagealni refluks ili GERD.
Total number of animals in the group 
Broj objave europskog patenta:
The process of claim 9, wherein the amine is monoethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, dimethylethylamine, or triethylamine. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se amin bira iz skupine koju čine monoetanolamin, dietanolamin, trietanolamin, dimetiletanolamin, dimetiletilamin 1 trietilamin.
wherein the variables are as defined in claim 1 . 
pri čemu su varijable kako je definirano u zahtjevul.
The ophthalmic or otorhinolaryngological device of claim 18 wherein the ophthalmic or otorhinolaryngological device is an intraocular lens. 
Oftalmički ili otorinolaringološki uređaj u skladu s patentnim zahtjevom 20, naznačen time što navedeni oftalmički ili otorinolaringološki uređaj je intraokularna leća.
increasing the temperature of the frozen product; 
podizanje temperature zamrznutog proizvoda;
a measured concentration of CA19-9, a measured concentration of Insulin-like growth factor-binding protein 7, 
izmjerene koncentracija čimbenika zgrušavanja VII, izmjerene koncentracije CA19-9.
the second accumulation value is not updated with the TPC command transmitted in the specific subframe if the specific subframe does not include the transmission request. 
prva akumulacijska vrijednost, prije nego što se podvrgne navedenom ažuriranju s naredbom TPC, postavljena na nulu nakon navedenog iniciranja.
Another embodiment includes a method of manufacturing a pharmaceutical composition comprising: recombinantly producing a therapeutic protein of interest which is rFVIII using a host cell within a medium; filtering the medium using a CUNO depth filter with a positive charge; exposing the depth filter to a salt elution buffer with a conductivity of at least 20 mS/cm to release protein of interest from the filter; recovering released protein of interest from the salt elution buffer; recovering further protein of interest from the sample passed through the depth filter; and combining recovered protein of interest with pharmaceutically acceptable carriers thereby forming the pharmaceutical composition. 
Metoda za proizvodnju terapijskog sastava obuhvaća: rekombinantnu proizvodnju terapijskog proteina od interesa koristeći stanicu domaćina unutar medija; filtriranje medija koristeći dubinski filtar s pozitivnim nabojem; izlaganje dubinskog filtra soli elucijskog pufera provodljivosti od najmanje 20 mS/em zbog oslobađanja proteina od interesa iz filtra; obnavljanje oslobođenog proteina od interesa iz soli elucijskog pufera; obnavljanje daljnjeg proteina od interesa iz uzorka koji je prošao kroz dubinski filtar; kombiniranje obnovljenog proteina od interesa s farmaceutski prihvatljivim nosačima tako tvoreći farmaceutski sastav.
a mechanical treatment which is selected from a treatment with a mixer, a treatment with an homogenizer, and a treatment with a mill;, and/or 
(ii) mehaničkom obradom koja je odabrana od tretmana s mikserom, tretmana s homogenizatorom i tretmana s mlinom; i/ili
Procedure according to claim 12, in which the acidification is carried out by adding a mixture of CO2 and air to the culture. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se zakiseljavanje provodi dodavanjem smjese CO, i zraka u kulturu.
with a compound of Formula V wherein R1 is as defined above, in the presence a heterogeneous acid scavenger. 
Lo Ž Formula V gdje je R1 kako je prethodno definiran, u prisutnosti heterogenog hvatača kiselina.
Biotin for use thereof in the treatment of neurological sequelae after multiple sclerosis attacks. 
Biotin naznačen time da je za uporabu za liječenje neuroloških posljedica nakon napada multiple skleroze.
A compound selected from: 
je odabran od etila i izopropila.
A pharmaceutically acceptable liquid composition comprising carbidopa, 4% to 20% by weight levodopa; and arginine, wherein said composition has a pH of 9.1 to 9.8 at 25°C, and the molar ratio of levodopa plus carbidopa to the arginine is 1:1.8 to 1:3.5. 
Farmaceutski prihvatljivi tekući pripravak, naznačen time što sadrži karbidopu, 4% do 12%, težinski, levodope; i 9% do 30%, težinski, arginina, gdje navedeni pripravak ima pH od 9,2 do 9,8 na 25 °C, a molarni omjer između levodope plus karbidope i arginina je 1:1,8 do 1:3,5.
A method of treating cushing's disease in a subject in need thereof, which comprises administering microparticles wherein said microparticles comprising cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] in free form, salt form or protected form embedded in a polymer matrix wherein the polymer matrix comprises a linear and a star polylactide-co-glycolide. 
HR P20100190 T1 PATENTNI ZAHTJEVI 1. Mikročestice, naznačene time, da sadrže ciklo[(4-(NH>-C;H,-NH-CO-O-)Pro?-Phg-DTrp-Lys-Tyr(4-Bzl)Phe] u slobodnom obliku, obliku soli ili u zaštićenom obliku ugrađenom u polimerni matriks pri čemu polimerni matriks sadrži linearni i razgranati polilaktid-ko-glikolid.
A formulation of an isolated compound of formula I: where: is hydroxy or B-D-xylopyranoside, 
Formulacija izoliranog spoja formule I:, gdje: je hidroksi ili B-d-ksilopiranozid,
—S(—O-octanoyl) means a serine, the hydroxyl group of which is substituted by an octanoyl group; 
S(O-oktanoil) predstavlja serin, čija je hidroksilna skupina supstituirana s oktanoil skupinom,
3.5 mg of total aliphatic carboxylic acid(s) and aliphatic carboxylic acid salt(s)/m2 of mineral filler(s). 
3.5 mg ukupne količine alifatsko karboksilne kiseline (alifatskih karboksilnih kiselina) i soli alifatske karboksilne kiseline/m mineralnog odnosno mineralnih punila.
It is further preferred that Z is an amine of formula Z1 wherein R13, R14 and R15 are independently selected from H, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, CH2F, CHF2 and CF3, wherein halogen is independently selected from F, Cl, Br and I. 
E", gdje su R'?, R'* i R!? neovisno odabrani od sljedećih: H, halogen, (C;-Cs)alkil, (C;-Cs)alkoksi, CH2F, CHF, i CF3, pri čemu je halogen neovisno odabran od F, Cl, Br i I.
Ammonium chloride for use according to any one of claims 1 or 2, wherein said ammonium chloride is associated with interferons and antiviral for the improved treatment of viral hepatitis. 
Amonij klorid za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time, da je navedeni amonijev klorid asociran s interferonima i antivirusno za poboljšano liječenje virusnog hepatitisa.
The process of any one of claims 1-7 containing a further step of mixing the conjugate with further antigens optionally wherein the further antigens comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 S.pneumoniae saccharides selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigensom, gdje dodatni antigeni može uključivati u najmanju ruku 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 S. pneumoniae saharide, koji se biraju iz skupine koju čine 1, 2, 3, 4,5, 6A, 6B, TF, 8, ON, 9V, 10A, IA, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F i 33F.
A pharmaceutical formulation for use in the treatment of respiratory disease according to any of Claims 1 to 9 additionally comprising 6a, 9a-difluoro-17a-[(2-furanylcarbonyl)oxy]-11B-hydroxy-16a-methyl-3-oxo-androsta-1,4-diene-17B-carbothioic acid S-fluoromethyl ester: wherein Compound (II) is in the form of a dry powder composition. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što dodatno sadrži S-fluormetilni ester 60,9a-difluor-17a-[(2-furanilkarbonil)oksi]-11f-hidroksi-160-metil-3-oksoandrosta-1,4-dien-17f-karbotiojske kiseline: a CH,F Spoj (Il) gdje je Spoj (II) u obliku suhog praha kao pripravka.
(New Orleans, LA) 
Imreg (New Orleans, LA)
A compound or its stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 wherein said compound is selected from the group: or 
2. < Spoj ili njegov stereoizomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema zahtjevu 1 15
is 0, 1 or 2 with the proviso that n2 + n3 is 2, 3 or 4; and a bond represented by the symbol: 
je 0, 1 ili 2, uz uvjet da n2 + n3 je 2, 3 ili 4; i gdje veza koju prikazuje simbol:
The isolated antibody for use according to any one of claims 1-6 or 10, wherein the antibody comprises a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 48. 
Izolirano protutijelo prema zahtjevu 1 ili zahtjevu 5, naznačeno time, da navedeno protutijelo sadrži konstantno područje slabog lanca, koje ima aminokiselinsku sekvencu sadržanu u SEQ ID NO:48.
glycopyrronium bromide at a dosage in the range of from 5 to 26 µg per actuation; 
(a) < glikopironijev bromid u dozi u rasponu od 5 do 26 ug po aktiviranju;
preparing sample solutions of the amino acid components of the batch and of bromotyrosine; 
pripremanje otopina uzoraka aminokiselinskih komponenata glatiramer acetata i bromtirozina;
The compound of claim 1, wherein the compound of formula (I) is a compound of formula (IB): 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule (1) spoj formule (IB): R,
Depending on the solubility characteristics of the film coating immediate release (water-soluble coating), extended release (water-insoluble coating) or delayed release (the solubility of the coating depends on the pH of the releasing medium) compositions can be prepared. 
Ovisno o svojstvu topljivosti tanke prevlake mogu se načiniti smjese s trenutnim otpuštanjem (prevlaka topljiva u vodi), produženim otpuštanjem (prevlaka netopljiva u vodi) ili odgođenim otpuštanjem (topljivost prevlake ovisi o pH vrijednosti medija za otpuštanje).
A method of producing a targeted therapeutic fusion protein comprising a step of: culturing mammalian cells in a cell culture medium, wherein the mammalian cells carry the nucleic acid of claim 14; and the culturing is performed under conditions that permit expression of the targeted therapeutic fusion protein. 
Postupak za proizvodnju ciljanog terapeutskog fuzijskog proteina naznačen time da sadrži korak: kultiviranja stanica sisavaca u mediju stanične kulture, pri čemu stanice sisavaca nose nukleinsku kiselinu prema zahtjevu 14; i kultiviranje se provodi pod uvjetima koji omogućuju ekspresiju ciljanog terapeutskog fuzijskog proteina.
The integrated rotary mixer and disperser head (1) according to any of the claims 1-16, wherein the discharge openings is a plurality of elongated, equally angularly spaced slots. 
Integrirana rotacijska miješalica 1 glava raspršivača (1) prema bilo kojoj od tvrdnji od 1 do 16 gdje otvore za pražnjenje čini mnoštvo izduženih, jednako kutno razmaknutih proreza.
As used herein, the term “antibody” is intended to encompass both whole antibodies and antibody fragments (e.g., antigen-binding fragments of antibodies, for example, Fv, Fc, Fd, Fab, Fab′, F(ab′), and dAb fragments). 
Humanizirano protutijelo prema zahtjevu 1, naznačeno time da je protutijelo fragment protutijela, poželjno pri čemu se fragment protutijela bira iz skupine koja se sastoji od Fab, Fab', F(ab*), i scFv.
None of the prior art documents addresses the problem of maintaining the desired polymorphic form of venlafaxine hydrochloride during the preparation of pharmaceutical dosage forms. 
Niti u jednom od dokumenata iz prethodnog stanja tehnike se ne spominje problem održavanja željenog polimorfnog oblika venlafaksin-hidroklorida prilikom dobivanja farmaceutskih oblika doziranja.
A thermally insulating stretchable down feathersheet (10) as claimed in claim 1 wherein said heat fusible elastomeric binding strands (15') are low molecularweight polymers having a softening point below 80 degrees C. 
Toplinski izolirajući rastezljivi sloj paperja (10) u skladu s patentnim zahtjevom 1, naznačen time što su navedena toplinski spojiva vezivna elastomerna vlakna (15’) niskomolekulski polimeri s točkom mekšanja ispod 80 °C.
The panel (1) according to claim 10, wherein the extension of the first sheet (2) is folded on the second flat surface (4) of the first sheet (2). 
. Ploča (1) prema zahtjevu 10, naznačena time što je proširenje prve ploče (2) presavijeno na drugu ravnu površinu
Use according to claim 1 wherein the animal to be protected is a feline. 
Uporaba prema zahtjevu 1, naznačena time, da se kod životinje koja se treba zaštititi, radi o mački.
The dismantling system (5) according to claim 1, wherein the retaining elements (52) comprise at least one flange suitable for holding the casing (12) via driving said flange on a base of the casing (12). 
Sustav za rastavljanje (5) u skladu s patentnim zahtjevom 1, naznačen time što element za držanje (52) ima najmanje jednu prirubnicu, pogodan za držanje kućišta (12), pokretanjem navedene prirubnice na podnožje kućišta
a drive unit arranged to adjust the at least one of firmness and height of said at least one zone; 
pogonsku jedinicu (4) postavljenu radi podešavanja čvrstoće navedene barem jedne zone;
A product for use according to claim 10, which further comprises an active compound (c), as defined in claim 5 or 6. 
Proizvod sukladno patentnom zahtjevu 13, naznačen time, da dodatno sadrži djelatni spoj (c) kako je definiran u patentnom zahtjevu 9 ili 10.
According to the present invention, there is provided a connecting member insertable inside a bone structure of a human or animal body, as claimed in Claim 1. 
(54) Naziv izuma: SPOJNI DIO KOJI SE UMEĆE UNUTAR STRUKTURE KOSTI LJUDSKOG ILI ŽIVOTNIJSKOG TIJELA, TE PRIPADAJUĆI SUSTAV PRONALAŽENJA
The process of paragraph 46, wherein said first solvent is selected from the group consisting of xylene, N-methylpyrrolidinone, Dimethylsulfoxide, diphenyl ether, and Dimethylacetamide, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno prvo otapalo se bira iz skupine koju čino ksilen, V-metilpirolidinon, dimetil-sulfoksid, difenil-eter i dimetilacetamid, te smjese 2 ili više njih.
binding a first etanercept-containing protein mixture comprising both correctly folded and incorrectly folded conformations of etanercept to a mixed mode chromatography resin having both ion exchange moieties and hydrophobic moieties; 
(a) vezanje prve mješavine proteina koja sadrži etanercept i to pravilno presavijenu i nepravilno presavijenu konformaciju etanercepta za mješovitu kromatografsku smolu koja ima obje ionske izmjene, i hidrofobne radikale;
A pharmaceutical composition for the treatment or prevention of HCV infection, comprising an effective amount of a compound according to one or more of the claims 1 to 11, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da služi za liječenje ili prevenciju HCV-infekcije, te da sadrži učinkovitu količinu spoja prema jednom ili više od zahtjeva 1 do Il, ili njegove farmaceutski prihvatljive soli ili njegovog estera, kao 1 farmaceutski prihvatljiv nosač.
Y is phenyl substituted with alkynyl, or fused with another 3-8 membered ring; and Z is N or C-CN. 
Y je fenil supstituiran sa alkinilom, ili spojen sa drugim prstenom od 3-8 članova; te Z je N ili C-CN.
Rb2 and Rb3 and/or Rb5 and Rb6 may be connected to form a cycloalkyl or a heterocycle, 
Rb, i Rbz i/ili Rbs i Rbg mogu biti spojeni za tvorbu cikloalkila ili heterocikla, uz uvjet da najmanje jedan od
The method of claim 11, wherein the Gram-negative bacterium is selected from the group consisting of Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae . 
Spoj za uporabu prema zahtjevu 9, naznačen time da je Gram-negativna bakterija odabrana iz skupine koja se sastoji od bakterija Pseudomonas aeruginosa, Acinetobacter baumannii, i Klebsiella pneumonia.
Use of a polymer washout solvent according to one of the preceding claims 1-9, for developing a flexographic printing plate in a washing step. 
Uporaba otapala za ispiranje polimera prema jednom od prethodnih zahtjeva 1-8, naznačena time da se u koraku ispiranja koristi za razvijanje fleksografske tiskarske ploče.
The use of filtration to reduce the particle size of crosslinked PMMA has never been considered, as it has been found that after initial filtration (effected for example by a filter presenting a minimum passage aperture of 70 micron), the ground crosslinked PMMA particles (for example of initial diameter 10 mm) were not retained but instead downstream of the filter presented dimensions from 30 to 60 times greater than the aperture through which they had passed. 
Korištenje filtriranja za smanjenje veličine čestice umreženog PMMA nije nikada bilo razmatrano, budući da je bilo nađeno kako nakon početnog filtriranja (koje je učinjeno, na primjer, pomoću filtra koji ima minimalni otvor prolaza od 70 mikrona), smljevene čestice umreženog PMMA (na primjer, početnog promjera od 10 mm) nisu bile zadržane, već se umjesto toga u smjeru odvijanja postupka iza filtra pojavljuju dimenzije od 30 do 60 puta veće od otvora kroz koji su one prošle.
The composite stainless steel and wood barrel according to one of claims 1 to 3, wherein the inert materials comprises at least one material selected from the group consisting of paraffin coating, PVC, silicone, stainless steel and glass. 
Kombinirana bačva od nehrđajućeg čelika i drva, prema bilo kojem patentnom zahtjevu 1 do 3, naznačena time, da inertni materijali sadrže bar jedan materijal izabran iz grupe koja se sastoji od parafinske ovojnice, PVC-a, silikona, nehrđajućeg čelika 1 stakla.
The polypeptide of claim 1, wherein the valine at position 5 of the DE loop (SEQ ID NO: 39) is substituted with an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, S, and T. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što je valin na položaju 5 u petlji DE (SEQ ID NO: 39) zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, I, K, L, M, N, Q, S i T.
A compound of Formula (II) and pharmaceutically acceptable salts, or solvates thereof, wherein: 
Spoj s Formulom (II) [image] i njegove farmaceutski prihvatljive soli, ili solvati, naznačen time da:
the soluble hyaluronidase is formulated for administration as a ratio of hyaluronidase to IG of 10 U/gram (g) to 500 U/g of IG, whereby the amount of hyaluronidase in the composition is sufficient to effect increased bioavailability of the IG when administered in combination with the IG to at least 90% of the bioavailability of the same single dosage of IG administered via intravenous administration for treatment of the same IG-treatable disease or condition; 
topiva hijaluronidaza je formulirana za davanje kao omjer hijaluronidaze prema IG od 10 U/gram (g) do 500 U/g IG, pri čemu je količina hijaluronidaze u pripravku dovoljna za postizanje veće bioraspoloživosti IG kada se daje u kombinaciji s IG od barem 90% bioraspoloživosti iste jednostruke doze IG koja se daje pomoću intravenozne primjene za liječenje iste bolesti ili stanja koje se liječi pomoću IG;
A method for intramolecular homologous recombination in the genome of a plant cell, the method comprising the steps of: 
Postupak stimulacije intramolekularne homologne rekombinacije u genomu biljne stanice, naznačen time, da